ストックスクリーナーアプリを入手
21.80
1.22%
-0.27
プレマーケット:
21.99
0.19
+0.87%
前日終値:
$22.07
開ける：
$22.07
24時間の取引高:
2.25M
Relative Volume:
0.87
時価総額：
$2.11B
収益：
$610.16M
当期純損益:
$-532.93M
株価収益率:
-3.9431
EPS:
-5.5287
ネットキャッシュフロー:
$-442.30M
1週間 パフォーマンス:
-4.85%
1か月 パフォーマンス:
-11.71%
6か月 パフォーマンス:
-30.31%
1年 パフォーマンス:
-46.96%
1日の値動き範囲:
$21.47
$22.19
1週間の範囲:
$21.47
$23.45
52週間の値動き範囲:
$18.41
$42.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
名前
Ultragenyx Pharmaceutical Inc
セクター
電話
415-483-8800
住所
60 LEVERONI COURT, NOVATO, CA
Compare RARE vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
21.80 | 2.13B | 610.16M | -532.93M | -442.30M | -5.5287 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-07-28 | 再開されました | H.C. Wainwright | Buy |
| 2025-05-28 | 開始されました | William Blair | Outperform |
| 2024-06-06 | アップグレード | Goldman | Neutral → Buy |
| 2024-04-22 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-06-14 | 再開されました | Credit Suisse | Outperform |
| 2023-06-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-04-26 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-01-18 | 再開されました | Canaccord Genuity | Buy |
| 2022-12-30 | 再開されました | H.C. Wainwright | Buy |
| 2022-11-03 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-08-01 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-03-16 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-09-30 | 開始されました | H.C. Wainwright | Buy |
| 2021-08-19 | 開始されました | UBS | Sell |
| 2021-07-15 | 開始されました | Guggenheim | Neutral |
| 2021-06-29 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Neutral |
| 2021-05-06 | アップグレード | Citigroup | Neutral → Buy |
| 2021-05-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Neutral |
| 2021-03-02 | 再開されました | Stifel | Buy |
| 2021-02-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-12-07 | ダウングレード | Wedbush | Outperform → Neutral |
| 2020-11-24 | 再開されました | Evercore ISI | In-line |
| 2020-11-12 | ダウングレード | BofA Securities | Buy → Neutral |
| 2019-08-02 | 再開されました | Wedbush | Outperform |
| 2019-03-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | 再開されました | Raymond James | Outperform |
| 2019-01-02 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | アップグレード | Citigroup | Sell → Neutral |
| 2018-09-10 | 開始されました | Morgan Stanley | Equal-Weight |
| 2018-06-21 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | アップグレード | Barclays | Equal Weight → Overweight |
| 2018-05-10 | 開始されました | Goldman | Neutral |
| 2018-04-18 | アップグレード | SunTrust | Hold → Buy |
| 2018-03-22 | 再開されました | Piper Jaffray | Overweight |
| 2018-02-21 | 繰り返されました | Stifel | Buy |
| 2018-01-22 | アップグレード | Evercore ISI | In-line → Outperform |
| 2018-01-18 | 開始されました | Credit Suisse | Outperform |
| 2017-12-05 | 繰り返されました | Barclays | Equal Weight |
| 2017-12-04 | アップグレード | Jefferies | Hold → Buy |
| 2017-09-14 | アップグレード | Wedbush | Neutral → Outperform |
すべてを表示
Ultragenyx Pharmaceutical Inc (RARE) 最新ニュース
Skeletal Dysplasia Market - GlobeNewswire Inc.
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire
Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit: Investors Face April 6, 2026, Deadline - NewMediaWire
Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action LawsuitRGRD Law - PR Newswire
Robbins LLP Urges RARE Stockholders to Contact the Firm for - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
UPCOMING DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action – April ... - Bluefield Daily Telegraph
UPCOMING DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) - GlobeNewswire
Ultragenyx Pharmaceutical Inc. $RARE Shares Bought by Rafferty Asset Management LLC - MarketBeat
Ultragenyx EVP Pinion sells $228k in shares - Investing.com
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - GlobeNewswire Inc.
Navan, Inc. Notice of April 24, 2026 Application Deadline for Class Action Lawsuit - GlobeNewswire Inc.
Ultragenyx Pharmaceutical (NASDAQ:RARE) Insider Sells $228,661.20 in Stock - MarketBeat
Howard Horn Sells 1,635 Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) EVP Sells $185,478.00 in Stock - MarketBeat
Theodore Alan Huizenga Sells 1,632 Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) EVP Eric Crombez Sells 7,029 Shares - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) EVP Sells 10,539 Shares - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Sells $190,884.30 in Stock - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) CEO Sells 54,404 Shares - MarketBeat
Ultragenyx (RARE) EVP Harris receives stock award, sells shares for taxes - Stock Titan
Ultragenyx (RARE) legal chief receives stock award, sells shares for taxes - Stock Titan
Ultragenyx (RARE) CAO disposes shares in RSU tax-related transactions - Stock Titan
Ultragenyx (RARE) CFO nets stock award and sells 10,044 shares - Stock Titan
Ultragenyx (RARE) CMO reports stock award and sale of common shares - Stock Titan
Ultragenyx (RARE) executive reports stock grant and tax share surrender - Stock Titan
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit - PR Newswire
Experts: Regulatory roadblocks stalling rare disease therapies - BioWorld MedTech
Shareholders that lost money on Ultragenyx Pharmaceutical Inc.(RARE) Urged to Join Class ActionContact The Gross Law Firm to Learn More - PR Newswire
Howard Horn sells RARE shares (NASDAQ: RARE) in Form 144 disclosure - Stock Titan
Levi & Korsinsky, LLP: Section 10(b) and Rule 10b-5 Claims Filed Against Ultragenyx ... - Bluefield Daily Telegraph
Levi & Korsinsky, LLP: Section 10(b) and Rule 10b-5 Claims Filed Against Ultragenyx Pharmaceutical - marketscreener.com
NASDAQ: RARE Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ - marketscreener.com
Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit Seeks Recovery for Investors; April 6, 2026, DeadlineContact Kessler Topaz Meltzer & Check, LLP - PR Newswire
Ultragenyx Pharmaceutical Inc. Investors with Substantial - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors - GlobeNewswire
Ultragenyx Pharmaceutical Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsRARE - marketscreener.com
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm - marketscreener.com
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionRARE - ACCESS Newswire
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc.RARE - Sahm
Vanguard Group Inc. Sells 80,694 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
RARE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 – Company AnnouncementFT.com - Financial Times
69,248 Shares in Ultragenyx Pharmaceutical Inc. $RARE Purchased by Thornburg Investment Management Inc. - MarketBeat
Ultragenyx Pharmaceutical (RARE) Valuation Check After Recent Share Price Volatility - Yahoo Finance
Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitRARE - ChartMill
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutica - GuruFocus
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ultragenyx - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming DeadlinesRARE - PR Newswire
INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitRARE - TMX Newsfile
RARE CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - marketscreener.com
Ultragenyx Pharmaceutical Inc (RARE) 財務データ
収益
当期純利益
現金流量
EPS
0.11%
6.00%
大文字化:
|
ボリューム (24 時間):